Using engineered T cells to target and treat acute myeloid leukemia
Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia
['FUNDING_OTHER'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10862895
This study is testing a new treatment for acute myeloid leukemia (AML) that uses specially modified immune cells to target and attack leukemia cells, giving patients a promising option to fight their cancer more effectively.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10862895 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new therapy for acute myeloid leukemia (AML) by using chimeric antigen receptor (CAR) T cells that specifically target leukemia stem cells. The approach involves creating T cells that are genetically modified to recognize and attack cells expressing the CD371 antigen, which is found on the majority of AML cells but not on normal blood stem cells. By also incorporating the secretion of IL-18, the therapy aims to enhance the persistence of these T cells and improve the overall immune response against the leukemia. Patients may receive this treatment as a potential option to combat their AML more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with acute myeloid leukemia.
Not a fit: Patients with other types of leukemia or those who do not express the CD371 antigen may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more targeted and effective treatment option for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promise in using CAR T cell therapies for various cancers, indicating potential success for this novel approach in AML.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRENTJENS, RENIER JOSEPH — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: BRENTJENS, RENIER JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.